-+ 0.00%
-+ 0.00%
-+ 0.00%

IPO News | Zhiyuan Pharmaceutical Plans Hong Kong Stock IPO The Securities Regulatory Commission requested clarification on the background of the establishment of the equity incentive plan and the fairness of the share grant price

Zhitongcaijing·11/20/2026 11:33:05
Listen to the news

The Zhitong Finance App learned that on November 20, the China Securities Regulatory Commission announced the disclosure of supplementary materials for overseas issuance and filing (November 16, 2026 to November 20, 2026). Regarding equity incentives, the Securities Regulatory Commission requires Zhiyuan Pharmaceutical to explain the decision-making process for the repurchase of shares to determine the corresponding share transferor, the reasons and rationality of the pricing differences in the repurchase price, and issue clear concluding opinions on whether there is a transfer of benefits and undisclosed supplementary agreements affecting equity stability; the background of the establishment of the equity incentive plan and the fairness of the share grant price. According to the Hong Kong Stock Exchange's disclosure on July 9, Zhiyuan Pharmaceutical submitted a listing application to the main board of the Hong Kong Stock Exchange, and CITIC Securities was its sole sponsor.

In addition, the Securities Regulatory Commission requested that Zhiyuan Pharmaceutical provide additional explanations on the following matters, and ask lawyers to check and issue clear legal opinions:

Regarding historical developments, please explain: (1) the reason, rationality and pricing basis for the company's initial share transfer price reduction; whether the price was fair; whether approval was obtained from the competent department, whether the transfer procedure was in compliance, and whether there were cases of loss of collective assets; (2) The pricing basis for the company's previous capital increases and share transfers, 1 yuan, 1 yuan annualized interest, or zero consideration should explain the authenticity of the transaction, whether the investment was actually paid, and whether there were any flawed circumstances such as failure to fulfill investment obligations, evasion of investment, and investment methods, etc. and whether the successive equity changes are legal and compliant, are conclusive Opinions.

The list explains the names of the proxy holders in the company's historical history, the ratio of proxy shareholding, and the method of cancellation of proxy holdings, and further explains the reasons, evolution, legal compliance, whether there are disputes or potential disputes, and whether the proxy holder is prohibited from holding shares during the shareholding period in accordance with the relevant provisions of the “Guidelines for the Application of Regulatory Rules - Overseas Issuance and Listing Class No. 2”, and whether the proxy holder was a subject prohibited from holding shares under laws and regulations (including whether it violated the prohibition of competition).

Regarding overseas subsidiaries, please explain: (1) the specific situation of overseas operations, the implementation of regulatory procedures such as overseas investment and foreign exchange management involving the establishment of overseas subsidiaries; (2) whether the specific use of capital raised and the share of domestic and foreign countries are involved in specific overseas fund-raising projects, and issue concluding opinions on compliance.

Explain whether the shares held by shareholders who intend to participate in the “full circulation” have been pledged, frozen, or have other rights defects.

According to the prospectus, Zhiyuan Pharmaceutical is a Chinese pharmaceutical company focusing on the field of topical dermatology. It has leading products in various treatment fields and provides comprehensive “head to toe” solutions covering skin drugs and medical grade skincare products. The company's product portfolio covers all skin areas, including scalp and hair, face, trunk, limbs and nails. The six core treatment areas include nasofacial skin diseases, superficial fungal infections, onychomycosis, immunoinflammatory skin diseases, pigmentation-impaired skin diseases, and scalp and hair diseases. As of the last practical date, the company has commercialized more than 50 products in six core treatment areas.